Program
Omeprazole
Also written as “Atazanavir/Ritonavir+Omeprazole”, “omeprazole” and “Omeprazole 20 mg”.
Its studies are mostly in Gastroesophageal Reflux · Neoplasms · Laryngopharyngeal Reflux · Heartburn · HIV Infections, led by 13 companies.
Drug pageOmeprazole: every studyMany companies study it; this page follows only the 32 they lead. All 164 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 90 open or running | phase 4since Mar 18, 2008 | Nov 20, 2005 | none ahead |
| Bayerits history only | 40 open or running | phase 4since Apr 4, 2012 | May 2, 2008 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 8, 2010 | Jan 8, 2010 | none ahead |
| Boehringer Ingelheimits history only | 30 open or running | phase 1since Sep 30, 2014 | Sep 30, 2014 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 1since Mar 1, 2007 | Mar 1, 2007 | none ahead |
| Procter and Gambleits history only | 20 open or running | phase 4since Dec 15, 2008 | Dec 15, 2008 | none ahead |
| Sanofiits history only | 20 open or running | phase 3since Sep 2, 2009 | Sep 2, 2009 | none ahead |
| AbbVieits history only | 10 open or running | phase 3since Apr 29, 2008 | Apr 29, 2008 | none ahead |
| Ascension Healthits history only | 10 open or running | phase 4since Jan 25, 2013 | Jan 25, 2013 | none ahead |
| Nekkar Lab Srlits history only | 11 open or running | no phasesince Oct 14, 2019 | Oct 14, 2019 | none ahead |
| Perle Bioscienceits history only | 10 open or running | phase 3since Jan 2, 2013 | Jan 2, 2013 | none ahead |
| PT Kalbe Farma Tbkits history only | 10 open or running | no phasesince Feb 8, 2023 | Feb 8, 2023 | none ahead |
| SD Biosensorits history only | 10 open or running | phase 4since Jan 19, 2009 | Jan 19, 2009 | none ahead |
Also a collaborator on its studies: PT Pharma Metric Labs, Parexel, Medpace, Syreon, Bausch Health Companies, Ferring Pharmaceuticals and Tanabe Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Nov 20, 2005.
- Apr 15, 2011Phase 1 study in HeartburnBayer · NCT01337804 · 50 enrolled
- Feb 10, 2012Phase 1 study in Carcinoma, MedullarySanofi · NCT01539655 · 34 enrolled · United States
- Apr 4, 2012Phase 4 study in HeartburnBayer · NCT01587885 · 48 enrolled
- Jan 2, 2013Perle Bioscience’s first study: phase 3 study in Diabetes Mellitus, Type 1New to Perle BiosciencePerle Bioscience · NCT01762644
- Jan 25, 2013Ascension Health’s first study: phase 4 study in Laryngopharyngeal RefluxNew to Ascension HealthAscension Health · NCT01777854 · 6 enrolled · United States
- Aug 5, 2013Phase 1 study in Bioequivalence, AUC, Cmax, PharmacokineticsAstraZeneca · NCT01921920 · 54 enrolled · United States
- Sep 30, 2014Boehringer Ingelheim’s first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT02253875 · 15 enrolled
- Jan 20, 2015Phase 1 study in HealthyBoehringer Ingelheim · NCT02345304 · Germany
- May 21, 2015Phase 1 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02453022 · 18 enrolled · United States
- Oct 14, 2019Nekkar Lab Srl’s first study: no phase study in Gastroesophageal RefluxNew to Nekkar Lab SrlNekkar Lab Srl · NCT04130659 · 110 planned · Italy, Romania
- Jun 8, 2021Phase 1 study in Advanced Solid TumoursAstraZeneca · NCT04959266 · 5 enrolled · United States, Spain
- Apr 1, 2022Phase 1 study in HealthyAstraZeneca · NCT05319912 · 18 enrolled · United States
- Feb 8, 2023PT Kalbe Farma Tbk’s first study: no phase study in Drug UseNew to PT Kalbe Farma TbkPT Kalbe Farma Tbk · NCT05849883 · 36 enrolled · Indonesia
- Feb 14, 2023No phase study in Liver CirrhosisBoehringer Ingelheim · NCT05741385 · 4 enrolled · Germany
TargetBeta
“Potassium-transporting ATPase inhibitor; Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05741385Liver Cirrhosis · Germany | – | Completed | Boehringer Ingelheim | Aug 9, 2024 | 4 |
| NCT05849883Drug Use · Indonesia | – | Completed | PT Kalbe Farma Tbk | Jan 14, 2021 | 36 |
| NCT05319912Healthy · United States | 1 | Completed | AstraZeneca | May 29, 2014 | 18 |
| NCT04959266Advanced Solid Tumours · United States, Spain | 1 | Terminated | AstraZeneca | Jun 1, 2022 | 5 |
| NCT04130659Gastroesophageal Reflux · Italy, Romania | – | Recruiting | Nekkar Lab Srl | Dec 31, 2024 | 110 |
| NCT02453022Pulmonary Disease, Chronic Obstructive · United States | 1 | Completed | GlaxoSmithKline | Jul 31, 2015 | 18 |
| NCT02345304Healthy · Germany | 1 | Withdrawn | Boehringer Ingelheim | Apr 2015 | 0 |
| NCT02253875Healthy | 1 | Completed | Boehringer Ingelheim | Feb 2006 | 15 |
| NCT01921920Bioequivalence, AUC, Cmax, Pharmacokinetics · United States | 1 | Completed | AstraZeneca | Nov 2013 | 54 |
| NCT01777854Laryngopharyngeal Reflux · United States | 4 | Terminated | Ascension Health | Jul 2015 | 6 |
| NCT01762644Diabetes Mellitus, Type 1 | 3 | Withdrawn | Perle Bioscience | May 2016 | 0 |
| NCT01587885Heartburn | 4 | Completed | Bayer | Apr 2012 | 48 |
| NCT01539655Carcinoma, Medullary · United States | 1 | Completed | Sanofi | Sep 2012 | 34 |
| NCT01337804Heartburn | 1 | Completed | Bayer | Jan 2011 | 50 |
| NCT01159145Pharmacodynamics Study · Japan | 1 | Completed | AstraZeneca | Sep 2010 | 42 |
| NCT01170182Healthy | 1 | Completed | Dr. Reddy's Laboratories | Apr 2006 | 54 |
| NCT01170169Healthy | 1 | Completed | Dr. Reddy's Laboratories | Mar 2006 | 44 |
| NCT01045642Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Dec 2006 | 38 |
| NCT01045434Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Jan 2007 | 62 |
| NCT00971581Pain · Mexico | 3 | Completed | Sanofi | May 2010 | 52 |
| NCT00903448Healthy · United States | 4 | Completed | Procter and Gamble | Jun 2009 | 40 |
| NCT00825630Helicobacter Pylori Infection · Israel | 4 | Completed | SD Biosensor | Nov 2009 | 123 |
| NCT00808769Normal Healthy Subject Population · United States | 4 | Completed | Procter and Gamble | Dec 2008 | 30 |
| NCT00765206Gastric Acid | 3 | Completed | Bayer | Aug 2008 | 60 |
| NCT00674115Gastric Acid | 3 | Completed | Bayer | Jun 2008 | 60 |
| NCT00669955Helicobacter Infections · United Kingdom | 3 | Completed | AbbVie | Jul 2009 | 440 |
| NCT00641264Laryngopharyngeal Reflux | 4 | Completed | AstraZeneca | Jun 2003 | 90 |
| NCT00443170Anemia · Australia | 1 | Completed | GlaxoSmithKline | 90 | |
| NCT00402259Gastrointestinal Hemorrhage · China | 3 | Completed | AstraZeneca | 440 | |
| NCT00259077Non-Erosive Reflux Disease · Japan | 3 | Completed | AstraZeneca | Jul 2004 | 270 |
| NCT00259051Non-Erosive Reflux Disease · Japan | 3 | Completed | AstraZeneca | Aug 2004 | 40 |
| NCT00256737Gastroesophageal Reflux · Denmark, Finland, Norway and more | 3 | Completed | AstraZeneca | Oct 2005 | 219 |
How it is read
Names in the registry
- “Omeprazole”, 30 entries
- “Atazanavir/Ritonavir+Omeprazole”, 4 entries
- “omeprazole”, 3 entries
- “Omeprazole 20 mg”, 2 entries
- “Omeprazole/sodium bicarbonate”, 2 entries
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 3 studies
- Neoplasms, 2 studies
- Laryngopharyngeal Reflux, 2 studies
- Heartburn, 2 studies
- HIV Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.